VIA
RNAC icon

Virtus Investment Advisers’s Cartesian Therapeutics RNAC Stock Holding History

Virtus Investment Advisers’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,112
Closed -$114K – 530
2025
Q3 		$114K Buy
11,112
+1,929
+21% +$21.7K 0.03% 411
2025
Q2 		$95.4K Buy
9,183
+1,023
+13% +$10.9K 0.03% 351
2025
Q1 		$108K Buy
+8,160
New +$146K 0.03% 411

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Virtus Investment Advisers's RNAC Position: Q4 2025 in Review

Virtus Investment Advisers sold out of Cartesian Therapeutics (RNAC) in Q4 2025, closing a stake of 11,112 shares — an estimated $114K sold.

Virtus Investment Advisers first reported a position in RNAC in Q1 2025 and held it in 3 quarters. The position peaked at $114K in Q3 2025. 67 funds tracked by Wall St. Rank hold RNAC as of Q4 2025.

  • Virtus Investment Advisers reported no remaining Cartesian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Virtus Investment Advisers sold 11,112 Cartesian Therapeutics shares in Q4 2025, an estimated $114K.
  • Virtus Investment Advisers first reported a position in Cartesian Therapeutics in Q1 2025 and held it in 3 quarters.
  • Virtus Investment Advisers's Cartesian Therapeutics position peaked at $114K in Q3 2025.
  • 67 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2025.

Based on Virtus Investment Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.